These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 15950009)
21. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. Sangal RB; Sangal JM Clin Neurophysiol; 2006 Sep; 117(9):1996-2006. PubMed ID: 16890481 [TBL] [Abstract][Full Text] [Related]
22. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. Laucht M; Skowronek MH; Becker K; Schmidt MH; Esser G; Schulze TG; Rietschel M Arch Gen Psychiatry; 2007 May; 64(5):585-90. PubMed ID: 17485610 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077 [TBL] [Abstract][Full Text] [Related]
24. [Alterations in the pattern of dopaminergic markers in attention-deficit/hyperactivity disorder]. Díaz-Heijtz R; Mulas F; Forssberg H Rev Neurol; 2006 Feb; 42 Suppl 2():S19-23. PubMed ID: 16555214 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134 [TBL] [Abstract][Full Text] [Related]
26. [Genetic background of ADHD: population studies, genes of the catecholamine system]. Słopién A; Dmitrzak-Weglarz M; Rybakowski F; Rajewski A; Hauser J Psychiatr Pol; 2006; 40(1):19-31. PubMed ID: 16756025 [TBL] [Abstract][Full Text] [Related]
27. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Polanczyk G; Zeni C; Genro JP; Roman T; Hutz MH; Rohde LA Pharmacogenomics; 2005 Apr; 6(3):225-34. PubMed ID: 16013954 [TBL] [Abstract][Full Text] [Related]
28. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
29. [Combination of DRD4 and DAT1 genotypes is an important risk factor for attention deficit disorder with hyperactivity families living in Santiago, Chile]. Henríquez B H; Henríquez H M; Carrasco Ch X; Rothhammer A P; Llop R E; Aboitiz F; Rothhammer E F Rev Med Chil; 2008 Jun; 136(6):719-24. PubMed ID: 18769827 [TBL] [Abstract][Full Text] [Related]
30. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder. Staller JA; Faraone SV Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490 [TBL] [Abstract][Full Text] [Related]
31. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Cheon KA; Cho DY; Koo MS; Song DH; Namkoong K Biol Psychiatry; 2009 Apr; 65(7):564-70. PubMed ID: 19150055 [TBL] [Abstract][Full Text] [Related]
32. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434 [TBL] [Abstract][Full Text] [Related]
33. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pietrzak RH; Mollica CM; Maruff P; Snyder PJ Neurosci Biobehav Rev; 2006; 30(8):1225-45. PubMed ID: 17161238 [TBL] [Abstract][Full Text] [Related]
34. Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype. Bellgrove MA; Hawi Z; Kirley A; Gill M; Robertson IH Neuropsychologia; 2005; 43(13):1847-57. PubMed ID: 16168728 [TBL] [Abstract][Full Text] [Related]
35. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227 [TBL] [Abstract][Full Text] [Related]
37. Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics. Rohde LA; Roman T; Hutz MH Pharmacogenomics J; 2003; 3(1):11-3. PubMed ID: 12629578 [No Abstract] [Full Text] [Related]
38. Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research. Elsayed NA; Yamamoto KM; Froehlich TE CNS Drugs; 2020 Apr; 34(4):389-414. PubMed ID: 32133580 [TBL] [Abstract][Full Text] [Related]
39. Whither causal models in the neuroscience of ADHD? Coghill D; Nigg J; Rothenberger A; Sonuga-Barke E; Tannock R Dev Sci; 2005 Mar; 8(2):105-14. PubMed ID: 15720368 [TBL] [Abstract][Full Text] [Related]
40. Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. Kebir O; Tabbane K; Sengupta S; Joober R J Psychiatry Neurosci; 2009 Mar; 34(2):88-101. PubMed ID: 19270759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]